Researchers at Memorial Sloan-Kettering Cancer Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for an ultrasmall inorganic (silica) nanoparticle platform for tumor targeting and for the treatment of cancers in the future.
A class of engineered nanoparticlesRaman-silica-gold-nanoparticleshas been shown to be safe when administered by two alternative routes in mouse models, according to a study published April 20 in Science Translational Medicine. This marks the first step up the ladder of toxicology studies that, within a year and a half, could yield to human trials of these agents for detection of colorectal and possibly other cancers.
Fleming Pharmaceuticals has ramped up production of ThyroShield, a liquid potassium iodide product indicated for thyroid protection in radiation emergencies, to meet increased domestic and international demand.
Avoiding contact laxatives is necessary to decrease intestinal artifacts in PET/CT image interpretation and a low-residue diet is not beneficial for colonic preparation, according to a study published in the April issue of Nuclear Medicine Communications.
ImaginAb and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with PET.